Abstract | OBJECTIVE:
Constipation is one of the most common gastrointestinal complications suspected to degrade the quality of life in diabetic patients. Mosapride citrate is a novel selective 5-HT4 receptor agonist, which enhances gastric emptying and motility in the upper gastrointestinal tract facilitating acetylcholine release from the enteric cholinergic neurons. Since the receptors of 5-HT4 have been recently found in the lower intestine including the rectum in humans, we tested if mosapride improves constipation in diabetic patients. PATIENTS AND METHODS: Diabetic patients with constipation were treated with mosapride citrate (15 mg/day, n=20) or domperidone (30 mg/day, n=12) as controls for 8 weeks. Bowel frequency was monitored and gastrointestinal symptoms were evaluated by Gastrointestinal Symptoms Rating Scale (GSRS). RESULTS: CONCLUSIONS: Administration of mosapride increased bowel frequency and ameliorated symptoms of reflux and constipation possibly stimulating the lower intestine. Given that mosapride has those beneficial aspects, it may be a useful prokinetic agent in treating diabetic patients with constipation.
|
Authors | Naohiko Ueno, Akio Inui, Yoshiko Satoh |
Journal | Diabetes research and clinical practice
(Diabetes Res Clin Pract)
Vol. 87
Issue 1
Pg. 27-32
(Jan 2010)
ISSN: 1872-8227 [Electronic] Ireland |
PMID | 19889470
(Publication Type: Journal Article)
|
Copyright | Copyright 2009 Elsevier Ireland Ltd. All rights reserved. |
Chemical References |
- Benzamides
- Blood Glucose
- Glycated Hemoglobin A
- Morpholines
- Serotonin Receptor Agonists
- mosapride
|
Topics |
- Aged
- Benzamides
(therapeutic use)
- Blood Glucose
(drug effects, metabolism)
- Body Mass Index
- Constipation
(drug therapy)
- Defecation
(drug effects, physiology)
- Diabetes Complications
(drug therapy)
- Diabetes Mellitus, Type 1
(complications)
- Diabetes Mellitus, Type 2
(complications)
- Female
- Glycated Hemoglobin
(drug effects, metabolism)
- Humans
- Male
- Middle Aged
- Morpholines
(therapeutic use)
- Serotonin Receptor Agonists
(therapeutic use)
|